Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

Company Overview

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations. In addition to FHD-286, Foghorn maintains a pipeline of preclinical programs aimed at other chromatin targets, with the goal of advancing multiple development candidates into the clinic over the coming years.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics was established with support from leading life-science investors. The company operates research and development activities in the United States and collaborates with academic and industry partners to accelerate the translation of its discoveries into potential therapeutic options for patients worldwide.

Under the leadership of President and Chief Executive Officer Robert Mulroy, PhD, Foghorn has built a multidisciplinary team with expertise in epigenetics, medicinal chemistry, structural biology and translational medicine. The company’s strategic vision emphasizes innovation in chromatin biology and a commitment to developing differentiated treatments for oncology.

Key Stats

• Today's Range: $3.77 to $4.03
• 50-Day Range: $3.79 to $5.78
• 52-Week Range: $3.27 to $6.95
• Volume: 257,874 shs
• Average Volume: 128,321 shs
• Market Capitalization: $222.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.43
• Consensus Rating: Moderate Buy

Foghorn Therapeutics Stock Analysis - MarketRank™

Foghorn Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 342nd out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Foghorn Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Foghorn Therapeutics has a consensus price target of $11.43, representing about 201.5% upside from its current price of $3.79.

Amount of Analyst Coverage

Foghorn Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Foghorn Therapeutics are expected to grow in the coming year, from ($0.98) to ($0.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Foghorn Therapeutics is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Foghorn Therapeutics is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.50% of the float of Foghorn Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Foghorn Therapeutics has a short interest ratio ("days to cover") of 11.85, which indicates bearish sentiment.

Change versus previous month

Short interest in Foghorn Therapeutics has recently decreased by 1.33%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Foghorn Therapeutics does not currently pay a dividend.

Dividend Growth

Foghorn Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.99

News Sentiment

Foghorn Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Foghorn Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for FHTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.58% of the stock of Foghorn Therapeutics is held by insiders.

Percentage Held by Institutions

61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/17/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FHTX
• CIK: 1822462
• Web: foghorntx.com
• Phone: 617-586-3100
• Fax: N/A
• Employees: 120
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Foghorn Therapeutics: $11.43
• High Price Target: $13.00
• Low Price Target: $10.00
• Potential Upside/Downside: +201.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.28 million
• Net Margins: -266.88%
• Pretax Margin: -266.88%
• Return on Equity: N/A
• Return on Assets: -35.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.92
• Quick Ratio: 2.92

Sales & Book Value

• Annual Sales: $30.91 million
• Price / Sales: 7.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.92) per share
• Price / Book: -1.97

Miscellaneous

• Outstanding Shares: 58,710,000
• Free Float: 54,263,000
• Market Cap: $222.51 million
• Optionable: Optionable
• Beta: 2.97